Status:
TERMINATED
Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer
Lead Sponsor:
West Virginia University
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will help researchers test the safety of hypofractionated dose of radiotherapy (HySBst) at different dose levels before or after chemo-radiation for Non Small Cell Lung Cancer.
Detailed Description
Patients are assigned to Sub-group 1 or 2 based on the primary lesion size and location. This protocol will utilize a standard 3 + 3 phase I design with three patients enrolled per cohort. Patients w...
Eligibility Criteria
Inclusion
- Stage II - III Non Small Cell Lung Cancer
Exclusion
- Primary tumor directly invading into any mediastinal structures, such as the heart, major blood vessels, esophagus, trachea, and the proximal bronchial tree.
- Prior chemotherapy for NSCLC
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
- Severe, active co-morbidity
- Pregnancy or women of childbearing potential
- Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin
- Uncontrolled neuropathy ≥ grade 2.
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2017
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT02252796
Start Date
July 1 2014
End Date
September 1 2017
Last Update
May 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West Virginia University Hospitals Mary Babb Randolph Cancer Center
Morgantown, West Virginia, United States, 26506